It is composed of two identical subunits which are held together by disulfide bonds. The monomer of this protein has structural similarity to several members of the beta-galactoside-binding S-type lectin family, but it could not bind beta-galactoside. This is because the ligand binding site is lack of key residue for binding beta-galactoside. [3]It is a galectin-like protein. The ligand of this protein is still unknown.
Clinical significance
PP13 levels that are low in the first trimester of pregnancy confers a higher risk for developing pre-eclampsia later in pregnancy.[4]
References
↑Bohn H, Kraus W, Winckler W (Jul 1983). "Purification and characterization of two new soluble placental tissue proteins (PP13 and PP17)". Oncodevelopmental Biology and Medicine. 4 (5): 343–50. PMID6856484.
↑Than NG, Sumegi B, Than GN, Berente Z, Bohn H (November 1999). "Isolation and sequence analysis of a cDNA encoding human placental tissue protein 13 (PP13), a new lysophospholipase, homologue of human eosinophil Charcot-Leyden Crystal protein". Placenta. 20 (8): 703–10. doi:10.1053/plac.1999.0436. PMID10527825.
↑Su J, Wang Y, Si Y, Gao J, Song C, Cui L, Wu R, Tai G, Zhou Y (January 2018). "Galectin-13, a different prototype galectin, does not bind β-galacto-sides and forms dimers via intermolecular disulfide bridges between Cys-136 and Cys-138". Scientific Reports. 8 (1): 980. doi:10.1038/s41598-018-19465-0. PMID29343868.
↑Huppertz B, Meiri H, Gizurarson S, Osol G, Sammar M (February 2013). "Placental protein 13 (PP13): a new biological target shifting individualized risk assessment to personalized drug design combating pre-eclampsia". Human Reproduction Update. 19 (4): 391–405. doi:10.1093/humupd/dmt003. PMID23420029.